Subcutaneous · GLP-1 / glucagon dual
OPK88003
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
1
Sites
3
Countries
1
Endpoints
4
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 2
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
2
Glycemic / diabetes
2
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03406377Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects | OPK88003 Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 2 | Completed | 3 | Mar 2019 | - | results |
Showing 1-1 of 1 trials